NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market yesterday a rise in its net loss for the third quarter as costs increased amid the ongoing rollout of its Candida test.

For the three-month period ended Sept. 30, the company posted revenues in the quarter of roughly $1 million, $245,000 from product sales and $804,000 in research revenues, compared with no revenues in the third quarter of 2014. Wall Street analysts, on average, had anticipated revenues of around $700,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.